z-logo
open-access-imgOpen Access
Invited commentary: When and how to initiate systemic therapy in treating favorable risk metastatic renal cell carcinoma
Author(s) -
Takahiro Inoue
Publication year - 2021
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1097/cu9.0000000000000052
Subject(s) - medicine , sunitinib , axitinib , renal cell carcinoma , nivolumab , oncology , pembrolizumab , cancer , immunotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom